Abbott Laboratories Net Income 2010-2022 | ABT

Abbott Laboratories annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Abbott Laboratories net income for the quarter ending March 31, 2022 was $2.447B, a 36.48% increase year-over-year.
  • Abbott Laboratories net income for the twelve months ending March 31, 2022 was $7.725B, a 34.96% increase year-over-year.
  • Abbott Laboratories annual net income for 2021 was $7.071B, a 57.31% increase from 2020.
  • Abbott Laboratories annual net income for 2020 was $4.495B, a 21.91% increase from 2019.
  • Abbott Laboratories annual net income for 2019 was $3.687B, a 55.7% increase from 2018.
Abbott Laboratories Annual Net Income
(Millions of US $)
2021 $7,071
2020 $4,495
2019 $3,687
2018 $2,368
2017 $477
2016 $1,400
2015 $4,423
2014 $2,284
2013 $2,576
2012 $5,963
2011 $4,728
2010 $4,626
2009 $5,746
Abbott Laboratories Quarterly Net Income
(Millions of US $)
2022-03-31 $2,447
2021-12-31 $1,989
2021-09-30 $2,100
2021-06-30 $1,189
2021-03-31 $1,793
2020-12-31 $2,162
2020-09-30 $1,232
2020-06-30 $537
2020-03-31 $564
2019-12-31 $1,049
2019-09-30 $960
2019-06-30 $1,006
2019-03-31 $672
2018-12-31 $654
2018-09-30 $563
2018-06-30 $733
2018-03-31 $418
2017-12-31 $-828
2017-09-30 $603
2017-06-30 $283
2017-03-31 $419
2016-12-31 $798
2016-09-30 $-329
2016-06-30 $615
2016-03-31 $316
2015-12-31 $767
2015-09-30 $580
2015-06-30 $784
2015-03-31 $2,292
2014-12-31 $905
2014-09-30 $538
2014-06-30 $466
2014-03-31 $375
2013-12-31 $590
2013-09-30 $966
2013-06-30 $476
2013-03-31 $544
2012-12-31 $1,053
2012-09-30 $1,943
2012-06-30 $1,725
2012-03-31 $1,242
2011-12-31 $1,619
2011-09-30 $303
2011-06-30 $1,943
2011-03-31 $864
2010-12-31 $1,441
2010-09-30 $891
2010-06-30 $1,292
2010-03-31 $1,003
2009-12-31 $1,539
2009-09-30 $1,480
2009-06-30 $1,288
2009-03-31 $1,439
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $192.394B $43.075B
Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $137.736B 18.33
Stryker (SYK) United States $88.212B 25.55
Boston Scientific (BSX) United States $56.697B 24.04
Baxter (BAX) United States $36.773B 19.27
ResMed (RMD) United States $28.798B 34.84
Zimmer Biomet Holdings (ZBH) United States $24.116B 15.83
Koninklijke Philips (PHG) Netherlands $22.053B 15.13
Bio-Rad Laboratories (BIO) United States $15.034B 32.60
Smith & Nephew SNATS (SNN) United Kingdom $13.676B 0.00
Envista Holdings (NVST) United States $6.789B 21.86
Perrigo (PRGO) Ireland $4.947B 19.56
BellRing Brands (BRBR) United States $3.371B 24.00
Haemonetics (HAE) United States $2.875B 21.71
Owens & Minor (OMI) United States $2.744B 10.10
Warby Parker (WRBY) United States $1.662B 0.00
Zevia PBC (ZVIA) United States $0.166B 0.00
Vapotherm (VAPO) United States $0.097B 0.00